DeKalb Genetics Corp., DeKalb, Ill., is studying whether to terminate its approximately $10 million defined benefit plan and possibly shift the assets into its $120 million defined contribution plan.
The defined benefit plan has been frozen since 1993. The corporation will be looking at all available options before officially terminating the plan, said Roger Maas, manager of retirement benefits at DeKalb.
The investment committee will need to decide whether to outsource record keeping, add two additional investment options, and hire a consultant to help with vendor selection, he said. The primary options the committee is considering are a small-cap equities fund and an international equity fund.